Publikace
- Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart2018 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo2015 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- The effects of bisphenols on the cardiovascular system ex vivo and in vivo2023 | Farmaceutická fakulta v Hradci Králové
- A Complex Methodological Approach for the Screening of Efficient and Safe Cobalt Chelators2023 | Farmaceutická fakulta v Hradci Králové
- Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- The effects of bisphenols on the cardiovascular system2022 | Farmaceutická fakulta v Hradci Králové
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Vitamin C-Sources, Physiological Role, Kinetics, Deficiency, Use, Toxicity, and Determination2021 | Farmaceutická fakulta v Hradci Králové
- Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin2021 | Farmaceutická fakulta v Hradci Králové
Loading network view...